PRX 00933

Drug Profile

PRX 00933

Alternative Names: 876167; ALT 933; BVT-933; GW 876167; PRX00933

Latest Information Update: 15 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biovitrum
  • Developer Altacor; Proximagen
  • Class Anorectics; Obesity therapies
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma; Obesity

Most Recent Events

  • 04 Aug 2015 Altacor has been acquired by Esperante Ventures
  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
  • 05 Mar 2012 No development reported - Phase-II for Obesity in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top